Top

Current Oncology Reports

Published in:

01-06-2022 | Carcinoid Tumor | Neuroendocrine Neoplasms (NS Reed, Section Editor)

Neuroendocrine Tumors: a Relevant Clinical Update

Authors: Emma N. Rizen, Alexandria T. Phan

Published in: Current Oncology Reports | Issue 6/2022

Abstract

Purpose of Review

The field of neuroendocrine oncology has changed much since the time of Oberndorfer first described and coined the term carcinoid. The purpose of this review is to summarize recent findings and highlight clinically relevant updates in the management of NENs, particularly those that are practice changing.

Recent Findings

Neuroendocrine tumors (NETs) have replaced carcinoid tumor, for the most part. The classification of neuroendocrine neoplasms (NENs) improved, and the epidemiological understanding of this disease group also expanded with global collaborations and maturation of large tumor registries. Clarity in the utility of some NET biomarkers continues to be evolving. Knowledge of molecular drivers of tumorigenesis increases, and scientific/technological advancements lead the way to multiple drug approvals for the treatment of advanced NETs.

Summary

The incidence and prevalence of NENs continue to increase, and patients are living longer. Better understanding of molecular drivers and further understanding of the role of immunotherapy in NENs will further elevate the level of care and transform care for all patients with NENs.

Oberndorfer S. Karzinoide tumoren des dunndarms. 1907. 1:426-432

Gosset A, Masson P. Tumeurs endocrines de l’appendice. Presse Med. 25:237–240.

Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol. 2004;35(12):1440–51. https://doi.org/10.1016/j.humpath.2004.09.018.CrossRefPubMed

Keener J, Sneyd J. Neuroendocrine cells. In: Keener J, Sneyd J, eds. Mathematical Physiology. Vol 8/1. Interdisciplinary Applied Mathematics. Springer New York; 2009:385–426. https://doi.org/10.1007/978-0-387-75847-3_9

Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511. https://doi.org/10.1210/er.2003-0014.CrossRefPubMed

Metovic J, Barella M, Bianchi F, et al. Morphologic and molecular classification of lung neuroendocrine neoplasms. Virchows Arch Int J Pathol. 2021;478(1):5–19. https://doi.org/10.1007/s00428-020-03015-z.CrossRef

Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 2013;40(1):120–33. https://doi.org/10.1053/j.seminoncol.2012.11.009.CrossRefPubMed

Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors version 2 2018. J Natl Compr Canc Netw. 2018;16(6):693–702.CrossRef

Fishbein L, Del Rivero J, Else T, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021;50(4):469–93. https://doi.org/10.1097/MPA.0000000000001792.CrossRefPubMed

10.

Rindi G, Inzani F. Neuroendocrine neoplasm update: toward universal nomenclature. Endocr Relat Cancer. 2020;27(6):R211–8. https://doi.org/10.1530/ERC-20-0036.CrossRefPubMed

11.

Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: a clinical snapshot. World J Gastrointest Surg. 2021;13(3):231–55. https://doi.org/10.4240/wjgs.v13.i3.231.CrossRefPubMedPubMedCentral

12.

Assarzadegan N, Montgomery E. What is new in the 2019 World Health Organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing. Arch Pathol Lab Med. 2021;145(6):664–77. https://doi.org/10.5858/arpa.2019-0665-RA.CrossRefPubMed

13.

Konukiewitz B, Schlitter AM, Jesinghaus M, et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol Off J U S Can Acad Pathol Inc. 2017;30(4):587–98.

14.

Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84. https://doi.org/10.1097/PAS.0b013e3182417d36

15.

• Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203. https://doi.org/10.1126/science.1200609. This is important because it is one of the few original data on molecular tumorigenesis of pancreatic NETs.

16.

Australian Pancreatic Cancer Genome Initiative, Scarpa A, Chang DK, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71. https://doi.org/10.1038/nature21063 This is important review on molecular landscape of small intestine NETs.CrossRef

17.

Scarpa A. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Ann Endocrinol. 2019;80(3):153–8. https://doi.org/10.1016/j.ando.2019.04.010.CrossRef

18.

Mafficini A, Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev. 2019;40(2):506–36. https://doi.org/10.1210/er.2018-00160.CrossRefPubMedPubMedCentral

19.

Cunningham JL, Díaz de Ståhl T, Sjöblom T, Westin G, Dumanski JP, Janson ET. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer. 2011;50(2):82–94. https://doi.org/10.1002/gcc.20834.CrossRefPubMed

20.

Karpathakis A, Dibra H, Pipinikas C, et al. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016;22(1):250–8. https://doi.org/10.1158/1078-0432.CCR-15-0373.CrossRefPubMed

21.

Andersson E, Swärd C, Stenman G, Ahlman H, Nilsson O. High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocr Relat Cancer. 2009;16(3):953–66. https://doi.org/10.1677/ERC-09-0052.CrossRefPubMed

22.

Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005;5(5):367–75. https://doi.org/10.1038/nrc1610.CrossRefPubMed

23.

Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2(7):851–6. https://doi.org/10.1093/hmg/2.7.851.CrossRefPubMed

24.

Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A Review of Von Hippel-Lindau syndrome. J Kidney Cancer VHL. 2017;4(3):20–9. https://doi.org/10.15586/jkcvhl.2017.88.CrossRefPubMedPubMedCentral

25.

Larson AM, Hedgire SS, Deshpande V, et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet. 2012;82(6):558–63. https://doi.org/10.1111/j.1399-0004.2011.01805.x.CrossRefPubMed

26.

Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81–8. https://doi.org/10.1136/jmg.2006.045906.CrossRefPubMed

27.

Geurts JL. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):559–66. https://doi.org/10.21037/jgo.2020.03.09.CrossRefPubMedPubMedCentral

28.

Fritz A. International Classification of Diseases for Oncology: ICD-O (Ed 3). World Health Organization; 2000. This is important because it is the largest reporting of epidemiologic study

29.

• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335. https://doi.org/10.1001/jamaoncol.2017.0589. This is important because it is the large USA population analysis leading to robust epidemiological understanding of NETs.

30.

Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes: neuroendocrine tumor epidemiology. Cancer. 2015;121(4):589–97. https://doi.org/10.1002/cncr.29099.CrossRefPubMed

31.

Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105(12):2563–9. https://doi.org/10.1038/ajg.2010.341.CrossRefPubMed

32.

Korse CM, Taal BG, van Velthuysen MLF. Visser O 2013 Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer Oxf Engl. 1990;49(8):1975–83. https://doi.org/10.1016/j.ejca.2012.12.022.CrossRef

33.

Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113(10):2655–64. https://doi.org/10.1002/cncr.23883.CrossRefPubMed

34.

Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58(2):368–79. https://doi.org/10.1007/s12020-017-1273-x.CrossRefPubMedPubMedCentral

35.

Lim CH, Lee IS, Jun BY, et al. Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience. Korean J Intern Med. 2017;32(3):452–8. https://doi.org/10.3904/kjim.2015.232.CrossRefPubMed

36.

JNETS Project Study Group, Masui T, Ito T, Komoto I, Uemoto S. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20(1):1104. https://doi.org/10.1186/s12885-020-07581-y.

37.

Fan JH, Zhang YQ, Shi SS, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget. 2017;8(42):71699–708. https://doi.org/10.18632/oncotarget.17599.CrossRefPubMedPubMedCentral

38.

Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44(3):157–65. https://doi.org/10.4143/crt.2012.44.3.157.CrossRefPubMedPubMedCentral

39.

Chauhan A, Yu Q, Ray N, et al. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018;9(27):19245–54. https://doi.org/10.18632/oncotarget.24983.CrossRefPubMedPubMedCentral

40.

Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(7):844–60. https://doi.org/10.1016/j.annonc.2020.03.304.CrossRef

41.

Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. https://doi.org/10.1200/JCO.2007.15.4377.CrossRefPubMed

42.

Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002.CrossRefPubMedPubMedCentral

43.

FDA-NIH Biomarker Working Group. BEST (biomarkers, endpoints, and other tools) resource. Food and Drug Administration (US); 2016. Accessed October 3, 2021. http://www.ncbi.nlm.nih.gov/books/NBK326791/

44.

Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–46. https://doi.org/10.1016/S1470-2045(15)00186-2.CrossRefPubMedPubMedCentral

45.

Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561–75. https://doi.org/10.1530/ERC-15-0092.CrossRefPubMed

46.

Modlin IM, Drozdov I, Kidd M. Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clin Chem Lab Med. 2014;52(3):419–29. https://doi.org/10.1515/cclm-2013-0496.CrossRefPubMed

47.

Öberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(2):202–12. https://doi.org/10.1016/j.annonc.2019.11.003.CrossRef

48.

Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinol. 2014;101(1):1–17. https://doi.org/10.1159/000367850.CrossRef

49.

Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303(21):1189–94. https://doi.org/10.1056/NEJM198011203032101.CrossRefPubMed

50.

Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin–doxorubicin, streptozocin–fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519–23. https://doi.org/10.1056/NEJM199202203260804.CrossRefPubMed

51.

Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(3):401–6. https://doi.org/10.1200/JCO.2005.03.6046.CrossRef

52.

Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2963–8. https://doi.org/10.1200/JCO.2011.40.3147.CrossRef

53.

Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(1):338–45. https://doi.org/10.1158/1078-0432.CCR-08-1476.CrossRef

54.

Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(9):759–67. https://doi.org/10.1530/ERC-16-0147.CrossRefPubMed

55.

Kunz PL, Catalano PJ, Nimeiri H, et al. 2018 A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15_supp):4004–4004. https://doi.org/10.1200/JCO.2018.36.15_suppl.4004.CrossRef

56.

Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10(2):282–91. https://doi.org/10.1200/JCO.1992.10.2.282.CrossRef

57.

Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83(12):855–61. https://doi.org/10.1093/jnci/83.12.855.

58.

Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(24):4665–72. https://doi.org/10.1200/JCO.2002.12.111.

59.

Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969–77.PubMed

60.

Kvols LK, Moertel CG, Óconnell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–6. https://doi.org/10.1056/NEJM198609113151102.CrossRefPubMed

61.

• Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63. https://doi.org/10.1200/JCO.2009.22.8510. The same pivotal and practice changing trials.

62.

• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33. https://doi.org/10.1056/NEJMoa1316158. The same pivotal and practice changing trials.

63.

• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427. The same pivotal and practice changing trials.

64.

Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(13):2124–30. https://doi.org/10.1200/JCO.2007.15.2553.CrossRef

65.

Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(8):1316–23. https://doi.org/10.1200/JCO.2007.13.6374.CrossRef

66.

Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(15):1695–703. https://doi.org/10.1200/JCO.2016.70.4072.CrossRef

67.

Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol. 2007;25(18_suppl):4504–4504. https://doi.org/10.1200/jco.2007.25.18_suppl.4504.

68.

Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–10. https://doi.org/10.1200/JCO.2007.15.9020.CrossRefPubMed

69.

Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16(6):695–703. https://doi.org/10.1016/S1470-2045(15)70136-1.CrossRefPubMedPubMedCentral

70.

Capdevila J, Fazio N, Lopez C, et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509). J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(20):2304–12. https://doi.org/10.1200/JCO.20.03368.CrossRef

71.

Chan JA, Faris JE, Murphy JE, et al. Phase trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors. J Clin Oncol. 2017;35(4_supp):228–228. https://doi.org/10.1200/JCO.2017.35.4_suppl.228.CrossRef

72.

• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. https://doi.org/10.1056/NEJMoa1003825. The same pivotal and practice changing trials.

73.

• Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489–99. https://doi.org/10.1016/S1470-2045(20)30493-9. The same pivotal and practice changing trials.

74.

• Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500–12. https://doi.org/10.1016/S1470-2045(20)30496-4. The same pivotal and practice changing trials.

75.

Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35. https://doi.org/10.1038/nrm3025.

76.

Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014;15(3):365–79. https://doi.org/10.1007/s11864-014-0294-4.

77.

Kasajima A, Pavel M, Darb-Esfahani S, et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18(1):181–92. https://doi.org/10.1677/ERC-10-0126.CrossRefPubMed

78.

Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(26):4311–8. https://doi.org/10.1200/JCO.2008.16.7858.CrossRef

79.

Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 2011;378(9808):2005–12. https://doi.org/10.1016/S0140-6736(11)61742-X.CrossRef

80.

• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23. https://doi.org/10.1056/NEJMoa1009290. The same pivotal and practice changing trials.

81.

• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 2016;387(10022):968–77. https://doi.org/10.1016/S0140-6736(15)00817-X. The same pivotal and practice changing trials.

82.

Yao JC, Strosberg J, Fazio N, et al. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. Published online January 1, 2021:ERC-20–0382.R1. https://doi.org/10.1530/ERC-20-0382

83.

Strosberg J, Mizuno N, Doi T, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(9):2124–30. https://doi.org/10.1158/1078-0432.CCR-19-3014.CrossRef

84.

Mehnert JM, Bergsland E, O’Neil BH, et al. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study. Cancer. 2020;126(13):3021–30. https://doi.org/10.1002/cncr.32883.CrossRefPubMed

85.

Klein O, Kee D, Markman B, et al. Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(17):4454–9. https://doi.org/10.1158/1078-0432.CCR-20-0621.CrossRef

86.

Patel SP, Othus M, Chae YK, et al. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(10):2290–6. https://doi.org/10.1158/1078-0432.CCR-19-3356.CrossRef

87.

Srinivasan R, Donskov F, Iliopoulos O, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(15_suppl):4555–4555. https://doi.org/10.1200/JCO.2021.39.15_suppl.4555.CrossRef

88.

Hörsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. Eur J Cancer Oxf Engl. 1990;2016(58):41–51. https://doi.org/10.1016/j.ejca.2016.01.009.CrossRef

89.

Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(16):4617–24. https://doi.org/10.1158/1078-0432.CCR-16-2743.CrossRef

90.

Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: eastern cooperative oncology group study E1281. J Clin Oncol. 2005;23(22):4897–904. https://doi.org/10.1200/JCO.2005.03.616.CrossRefPubMed

Title: Neuroendocrine Tumors: a Relevant Clinical Update
Authors: Emma N. Rizen
Alexandria T. Phan
Publication date: 01-06-2022
Publisher: Springer US
Keywords: Carcinoid Tumor
Neuroendocrine Tumor
Published in: Current Oncology Reports / Issue 6/2022
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-022-01217-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2022

Global Longitudinal Strain Monitoring to Guide Cardioprotective Medications During Anthracycline Treatment

Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy

Critical Review of the Current Evidence on Sentinel Node Biopsy in Oral Cancer

Challenges of Survivorship for Older Adults Diagnosed with Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer